Benefits and harms of plant-based Cannabis for posttraumatic stress disorder a systematic review

Maya E. O'Neil, Shannon M. Nugent, Benjamin J. Morasco, Michele Freeman, Allison Low, Karli Kondo, Bernadette Zakher, Camille Elven, Makalapua Motu'apuaka, Robin Paynter, Devan Kansagara

Research output: Contribution to journalReview article

  • 9 Citations

Abstract

Background: Cannabis is available from medical dispensaries for treating posttraumatic stress disorder (PTSD) in many states of the union, yet its efficacy in treating PTSD symptoms remains uncertain. Purpose: To identify ongoing studies and review existing evidence regarding the benefits and harms of plant-based cannabis preparations in treating PTSD in adults. Data Sources: MEDLINE, the Cochrane Library, and other sources from database inception to March 2017. Study Selection: English-language systematic reviews, trials, and observational studies with a control group that reported PTSD symptoms and adverse effects of plant-based cannabis use in adults with PTSD. Data Extraction: Study data extracted by 1 investigator was checked by a second reviewer; 2 reviewers independently assessed study quality, and the investigator group graded the overall strength of evidence by using standard criteria. Data Synthesis: Two systematic reviews, 3 observational studies, and no randomized trials were found. The systematic reviews reported insufficient evidence to draw conclusions about benefits and harms. The observational studies found that compared with nonuse, cannabis did not reduce PTSD symptoms. Studies had medium and high risk of bias, and overall evidence was judged insufficient. Two randomized trials and 6 other studies examining outcomes of cannabis use in patients with PTSD are ongoing and are expected to be completed within 3 years. Limitation: Very scant evidence with medium to high risk of bias. Conclusion: Evidence is insufficient to draw conclusions about the benefits and harms of plant-based cannabis preparations in patients with PTSD, but several ongoing studies may soon provide important results.

LanguageEnglish (US)
Pages332-340
Number of pages9
JournalAnnals of Internal Medicine
Volume167
Issue number5
DOIs
StatePublished - Sep 5 2017

Fingerprint

Cannabis
Post-Traumatic Stress Disorders
Observational Studies
Research Personnel
Information Storage and Retrieval
MEDLINE
Libraries
Language
Outcome Assessment (Health Care)
Databases
Control Groups

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Benefits and harms of plant-based Cannabis for posttraumatic stress disorder a systematic review. / O'Neil, Maya E.; Nugent, Shannon M.; Morasco, Benjamin J.; Freeman, Michele; Low, Allison; Kondo, Karli; Zakher, Bernadette; Elven, Camille; Motu'apuaka, Makalapua; Paynter, Robin; Kansagara, Devan.

In: Annals of Internal Medicine, Vol. 167, No. 5, 05.09.2017, p. 332-340.

Research output: Contribution to journalReview article

O'Neil, ME, Nugent, SM, Morasco, BJ, Freeman, M, Low, A, Kondo, K, Zakher, B, Elven, C, Motu'apuaka, M, Paynter, R & Kansagara, D 2017, 'Benefits and harms of plant-based Cannabis for posttraumatic stress disorder a systematic review' Annals of Internal Medicine, vol. 167, no. 5, pp. 332-340. DOI: 10.7326/M17-0477
O'Neil, Maya E. ; Nugent, Shannon M. ; Morasco, Benjamin J. ; Freeman, Michele ; Low, Allison ; Kondo, Karli ; Zakher, Bernadette ; Elven, Camille ; Motu'apuaka, Makalapua ; Paynter, Robin ; Kansagara, Devan. / Benefits and harms of plant-based Cannabis for posttraumatic stress disorder a systematic review. In: Annals of Internal Medicine. 2017 ; Vol. 167, No. 5. pp. 332-340
@article{1d42c8b5d71941abaaa772fd86562c88,
title = "Benefits and harms of plant-based Cannabis for posttraumatic stress disorder a systematic review",
abstract = "Background: Cannabis is available from medical dispensaries for treating posttraumatic stress disorder (PTSD) in many states of the union, yet its efficacy in treating PTSD symptoms remains uncertain. Purpose: To identify ongoing studies and review existing evidence regarding the benefits and harms of plant-based cannabis preparations in treating PTSD in adults. Data Sources: MEDLINE, the Cochrane Library, and other sources from database inception to March 2017. Study Selection: English-language systematic reviews, trials, and observational studies with a control group that reported PTSD symptoms and adverse effects of plant-based cannabis use in adults with PTSD. Data Extraction: Study data extracted by 1 investigator was checked by a second reviewer; 2 reviewers independently assessed study quality, and the investigator group graded the overall strength of evidence by using standard criteria. Data Synthesis: Two systematic reviews, 3 observational studies, and no randomized trials were found. The systematic reviews reported insufficient evidence to draw conclusions about benefits and harms. The observational studies found that compared with nonuse, cannabis did not reduce PTSD symptoms. Studies had medium and high risk of bias, and overall evidence was judged insufficient. Two randomized trials and 6 other studies examining outcomes of cannabis use in patients with PTSD are ongoing and are expected to be completed within 3 years. Limitation: Very scant evidence with medium to high risk of bias. Conclusion: Evidence is insufficient to draw conclusions about the benefits and harms of plant-based cannabis preparations in patients with PTSD, but several ongoing studies may soon provide important results.",
author = "O'Neil, {Maya E.} and Nugent, {Shannon M.} and Morasco, {Benjamin J.} and Michele Freeman and Allison Low and Karli Kondo and Bernadette Zakher and Camille Elven and Makalapua Motu'apuaka and Robin Paynter and Devan Kansagara",
year = "2017",
month = "9",
day = "5",
doi = "10.7326/M17-0477",
language = "English (US)",
volume = "167",
pages = "332--340",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "5",

}

TY - JOUR

T1 - Benefits and harms of plant-based Cannabis for posttraumatic stress disorder a systematic review

AU - O'Neil,Maya E.

AU - Nugent,Shannon M.

AU - Morasco,Benjamin J.

AU - Freeman,Michele

AU - Low,Allison

AU - Kondo,Karli

AU - Zakher,Bernadette

AU - Elven,Camille

AU - Motu'apuaka,Makalapua

AU - Paynter,Robin

AU - Kansagara,Devan

PY - 2017/9/5

Y1 - 2017/9/5

N2 - Background: Cannabis is available from medical dispensaries for treating posttraumatic stress disorder (PTSD) in many states of the union, yet its efficacy in treating PTSD symptoms remains uncertain. Purpose: To identify ongoing studies and review existing evidence regarding the benefits and harms of plant-based cannabis preparations in treating PTSD in adults. Data Sources: MEDLINE, the Cochrane Library, and other sources from database inception to March 2017. Study Selection: English-language systematic reviews, trials, and observational studies with a control group that reported PTSD symptoms and adverse effects of plant-based cannabis use in adults with PTSD. Data Extraction: Study data extracted by 1 investigator was checked by a second reviewer; 2 reviewers independently assessed study quality, and the investigator group graded the overall strength of evidence by using standard criteria. Data Synthesis: Two systematic reviews, 3 observational studies, and no randomized trials were found. The systematic reviews reported insufficient evidence to draw conclusions about benefits and harms. The observational studies found that compared with nonuse, cannabis did not reduce PTSD symptoms. Studies had medium and high risk of bias, and overall evidence was judged insufficient. Two randomized trials and 6 other studies examining outcomes of cannabis use in patients with PTSD are ongoing and are expected to be completed within 3 years. Limitation: Very scant evidence with medium to high risk of bias. Conclusion: Evidence is insufficient to draw conclusions about the benefits and harms of plant-based cannabis preparations in patients with PTSD, but several ongoing studies may soon provide important results.

AB - Background: Cannabis is available from medical dispensaries for treating posttraumatic stress disorder (PTSD) in many states of the union, yet its efficacy in treating PTSD symptoms remains uncertain. Purpose: To identify ongoing studies and review existing evidence regarding the benefits and harms of plant-based cannabis preparations in treating PTSD in adults. Data Sources: MEDLINE, the Cochrane Library, and other sources from database inception to March 2017. Study Selection: English-language systematic reviews, trials, and observational studies with a control group that reported PTSD symptoms and adverse effects of plant-based cannabis use in adults with PTSD. Data Extraction: Study data extracted by 1 investigator was checked by a second reviewer; 2 reviewers independently assessed study quality, and the investigator group graded the overall strength of evidence by using standard criteria. Data Synthesis: Two systematic reviews, 3 observational studies, and no randomized trials were found. The systematic reviews reported insufficient evidence to draw conclusions about benefits and harms. The observational studies found that compared with nonuse, cannabis did not reduce PTSD symptoms. Studies had medium and high risk of bias, and overall evidence was judged insufficient. Two randomized trials and 6 other studies examining outcomes of cannabis use in patients with PTSD are ongoing and are expected to be completed within 3 years. Limitation: Very scant evidence with medium to high risk of bias. Conclusion: Evidence is insufficient to draw conclusions about the benefits and harms of plant-based cannabis preparations in patients with PTSD, but several ongoing studies may soon provide important results.

UR - http://www.scopus.com/inward/record.url?scp=85028859886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028859886&partnerID=8YFLogxK

U2 - 10.7326/M17-0477

DO - 10.7326/M17-0477

M3 - Review article

VL - 167

SP - 332

EP - 340

JO - Annals of Internal Medicine

T2 - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 5

ER -